Compare LCID & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCID | BLTE |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.1B |
| IPO Year | N/A | 2022 |
| Metric | LCID | BLTE |
|---|---|---|
| Price | $11.20 | $169.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $24.00 | ★ $161.57 |
| AVG Volume (30 Days) | ★ 8.6M | 237.7K |
| Earning Date | 02-24-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,065,533,000.00 | N/A |
| Revenue This Year | $64.76 | N/A |
| Revenue Next Year | $84.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 45.86 | N/A |
| 52 Week Low | $9.50 | $49.00 |
| 52 Week High | $35.90 | $174.78 |
| Indicator | LCID | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 49.07 | 64.28 |
| Support Level | $10.55 | $156.52 |
| Resistance Level | $11.69 | $171.63 |
| Average True Range (ATR) | 0.64 | 8.88 |
| MACD | 0.14 | 0.26 |
| Stochastic Oscillator | 65.28 | 79.00 |
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations and through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.